WO2004106541A1 - 歯周病マーカー - Google Patents
歯周病マーカー Download PDFInfo
- Publication number
- WO2004106541A1 WO2004106541A1 PCT/JP2004/007867 JP2004007867W WO2004106541A1 WO 2004106541 A1 WO2004106541 A1 WO 2004106541A1 JP 2004007867 W JP2004007867 W JP 2004007867W WO 2004106541 A1 WO2004106541 A1 WO 2004106541A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- periodontal disease
- gingipain
- diagnosing
- amino acid
- detecting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
Definitions
- the present invention relates to a periodontal disease marker. More specifically, the present invention relates to a periodontal disease marker, a periodontal disease detection method and diagnostic method using the same, and a kit for detecting periodontal disease. Background art
- Periodontal disease is a major cause of tooth loss in adults, and is one of the so-called national illnesses, with an adult prevalence of more than 40%. In the past, periodontal disease was considered to be one of the physiological phenomena that occur with aging, and it was understood that tooth loss in aging was inevitable. Tooth loss not only causes a decrease in oral function, but also causes abnormalities in various nerve functions, and periodontal disease is a systemic disease (coronary heart disease, low birth weight child birth, preterm birth, diabetes, intracardiac It has been clarified that it is one of the risk factors for meningitis, cellular pneumonia, etc.), and overcoming periodontal disease is considered to be an indispensable issue to achieve an improvement in quality of life (QOL). Was.
- periodontal disease is an infection caused by bacteria in the subgingival plaque, and the primary purpose of treatment and prevention of periodontal disease is to control periodontopathogenic bacteria. It is believed that there is. Therefore, early and reliable diagnosis of periodontal disease is extremely important in establishing a new methodology for accurate treatment and prevention of this disease.
- a method for using saliva as a material for periodontal disease diagnosis is to add a substrate for 0-dalconidase to a saliva sample and measure the reaction product of / 3-dalconidase on the substrate.
- There has been proposed a method for measuring the concentration of ⁇ -dalconidase in the medium America Patent No. 66363588.
- this method is an accurate and reproducible method for diagnosing periodontal disease at an early stage and for reliable use. I have to say that there is something to improve.
- gingivalis a gram-negative anaerobic bacterium that is considered to be the main causative organism of periodontal disease. Genetic research has also been vigorously pursued for certain proteins and their cell surface proteins.
- the enzyme derived from B. gingivalis had a direct ability to degrade periodontal tissue mainly composed of collagen and also had a damaging activity on inflammatory cells such as neutrophils ( Japanese Patent Publication No. 7-13509773).
- This enzyme is a known 50 kDa cysteine protease derived from Porphyromonas gingivalis (Chen, Z., et al., J. Biol. Chem. 267: 18896-18901, 1992) and is sensitive to optimal pH and inhibitors. It is reported that the enzymological properties of individuals are similar, but differ in properties such as substrate specificity and thermostability.
- US Pat. No. 6,511,666 discloses a protein complex having nine protein fragments consisting of a small fragment of the amino acid sequence of arginine-specific and lysine-specific thiol-peptidase. It is described for use in inducing an immune response against P. gingivalis.
- gingipain is a group of enzymes constituting a unique family (C25) showing little similarity in amino acid sequence to other proteases, and it has a potent trypsin-like activity as, and from its base peptide binding disconnect specificity, C-terminal, side-specific a r g of arginine residues - gingipains (hereinafter, referred to as "R gp”) and It has been reported that it can be divided into Lys-gingipain (hereinafter referred to as “Kgpj”) specific to the C-terminal side of lysine residue (Kenji Yamamoto et al .: Molecular mechanism and biology of proteolysis-proteolysis (Suzuki .
- gingivalis which is considered to be a major causative microorganism of periodontal disease, in order to find an early and reliable means of diagnosing periodontal disease.
- Two types of cysteine proteases hereinafter “gingipain” (also referred to as “gingipain”) ⁇ ⁇
- the present invention can be used as a marker that can detect periodontal disease early, reliably, and easily, and completed the present invention.
- an object of the present invention is to provide a periodontal disease marker comprising using a cysteine protease (gingipain) produced by a gingivalis bacterium for detecting periodontal disease.
- a cysteine protease gingipain
- Another object of the present invention is to provide a method for detecting periodontal disease, comprising using the above-mentioned gingipain as a marker for detecting periodontal disease.
- Another object of the present invention is to provide a periodontal disease diagnosis method for diagnosing periodontal disease using saliva as a marker for detecting periodontal disease using gingipain.
- Another object of the present invention is to provide a periodontal disease diagnostic kit capable of easily diagnosing periodontal disease using gingipain as a periodontal disease detection marker. Disclosure of the invention
- the present invention provides a marker for detecting periodontal disease, comprising gingipain produced by gingivalis. Further, the present invention provides a method for using gingipain, which comprises using the gingipain as a marker for detecting periodontal disease, and a method for detecting periodontal disease, which detects periodontal disease using the gingipain as a periodontal disease marker. provide.
- the gingipain has Arg_ gingipain (R gp) having peptide bond cleavage specificity at the C-terminal side of arginine residue, and a peptide bond cleavage specificity at the C-terminal side of lysine residue. It is composed of Lys-gingipain (K gp), which has the following characteristics:
- the present invention also provides a method for diagnosing periodontal disease, comprising diagnosing periodontal disease using the gingipain as a marker for detecting periodontal disease.
- the present invention further provides a periodontal disease diagnostic kit capable of easily diagnosing periodontal disease using the gingipain as a periodontal disease detection marker.
- FIG. 1 is a diagram showing the results of measurement of K gp and R gp by Western blotting using an antibody.
- FIG. 2 is a diagram showing the results of measurement of K gp and R gp in saliva of periodontal disease patients by Western blotting using anti-K gp ⁇ R gp antibodies.
- FIG. 3 is a graph showing the results of measurement of K gp and R gp in saliva of a type I diabetic patient by Western blotting using an anti-K gp ⁇ R gp antibody.
- FIG. 3 is a view showing the results of measurement of Kgp and Rgp in saliva of a type I diabetic patient by Western blotting using an anti-Kgp ⁇ Rgp antibody.
- the present invention is characterized in that cystine protease (gingipain) produced by gingivalis is used as a marker for detecting periodontal disease.
- Zingipain used as a marker for detecting periodontal disease in the present invention is a group of enzymes constituting a unique family (C25) having little similarity in amino acid sequence to other proteases. It has a strong trypsin-like activity. Because of its peptide bond cleavage specificity, gingipain is characterized by Arg_gingipain (hereinafter referred to as “Rgp”) specific to the C-terminal side of arginine residues and Lys—specific to the C-terminal side of lysine residues.
- Rgp Arg_gingipain
- K gp Genzipain (hereinafter referred to as “K gp”) (Kenji Yamamoto et al .: Molecular mechanism and biology of proteolysis-proteolysis (Hiro Suzuki ⁇ Hidenori Kinanami, edited by Keiji Tanaka), extra edition of protein nucleic acid enzymes, PP. 2425-2431, Kyoritsu Shuppan (19 ⁇ 7); Yamamoto, K., et al .: Proteases: New Perspectives (Turk.!. Ed. ⁇ , pp. 175-183 ⁇ 4, Birkhauser Verlag, Basel (1999); Kenji Yamamoto: Cell Engineering, 19, 295-301 (2000); Kadowaki, T., et al .: J. Biochem., 128, 153-159 (2000)) Most of both enzymes exist as membrane-bound enzymes. However, some are secreted out of the cells as secretory forms, expressing their physiological and pathological effects.
- rgp A SEQ ID NO: 1 in the Sequence Listing
- rgp B SEQ ID NO: 2
- the rgpA gene has, in addition to the protease domain, a signal peptide and a propeptide at the N-terminal side and an adhesin domain at the C-terminal side.
- the adhesin domain is further composed of several subdomains that have hemagglutinin activity and hemoglobin binding activity (Fig. 1a).
- the signal peptide consists of 24 amino acids rich in hydrophobic amino acids, and is considered to be important for insertion of the gene product into the inner membrane after biosynthesis.
- the subsequent propeptide consisting of 203 amino acids is considered to be richer in basic amino acid than acidic amino acid, which contributes to the preservation of the higher-order structure of the enzyme molecule during the transport process.
- the adhesin domain shows an asymmetric distribution of polar amino acids and is acidic as a whole.
- This adhesin domain has an amphipatic strand structure characteristic of the transmembrane region of the outer membrane protein, and is thought to be transported and inserted into the outer membrane by this ( Non-patent document 7).
- an important subdomain of hemagglutinin and hemoglobin binding exists in this domain, which indicates the functional importance of the adhesin domain (Okamoto, K., et al .: Arch. Biochem. Biophys., 316, 917-925 (1995); Pavloff, N., et al .: J. Biol. Chem., 270, 1007-1010 (1995)).
- the enzyme secreted outside the cell is mainly composed of only the protease domain, except for the HG66 strain, which is mainly composed of a high-molecular-weight enzyme having an adhesin domain (Pike, R., et al .: J. Biol. Chem., 269, 406-411 (1994)).
- Membrane-bound enzymes that exist as a polymer complex in which the protease domain and the subdomain of the adhesin domain are non-covalently bound after the pre-peptide is removed, and those that consist only of the protease domain Exists.
- R gp can modify sugar chains (Curtis, MA, et al .: Infect. Immun., 67, 3816-3823 (1999)) and add lipopolysaccharide (Rangarajan, M., et al .: Mol. Microbiol , 23, 855-865 (1997)), and it is thought that various isozymes exist depending on the type of sugar and the degree of modification.
- the second gene, the rgpB gene is essentially identical to the rgpA gene except that it lacks most of the rgpA gene adhesin domain (identity of the prebub peptide and protease domains).
- Kgp is encoded by a single gene (kgp), and its gene product, like the gene product of RgpA, is derived from the signal peptide, propeptide, protease domain, and adhesin domains.
- Fig. 1a (Okamoto, ⁇ ⁇ , et al .: J. Biochem., 120, 398-406 (1996); Barcocy-Ganagher, GA, et al .: J. Bacteriol., 178, 2734) -2741 (1996); Pavloff, N., et al .: J. Biol. Chem., 272, 1593-1600).
- K gp Like R gp, some of K gp is transported outside the cell, and most of the rest is transported to the outer membrane. The extracellular one consists only of the protease domain, while the membrane-bound form is mainly composed of protease domain and adhesin. It exists as a complex of domain-derived subdomains (Fig. Lb) (Kenji Yamamoto et al. Protein Nucleic Acid Enzyme, Vol. 46, No. 11, pp. 1781-1427 (2001)).
- the catalytic domains of R gp and K gp have activity at almost the same position on the amino acid sequence. There is an essential His211 / Cys244 diad. X-ray crystal structure analysis of rgpB shows that this enzyme is a single polypeptide with a catalytic domain and an immunoglobulin superfamily domain, and the catalytic domain is further sandwiched between ⁇ helices. And six
- the method for detecting periodontal disease according to the present invention comprises detecting periodontal disease by measuring gingipain activity in a biological sample.
- Examples of the biological sample that can be used in the present invention include: groin exudate (GCF), saliva, serum, and the like.
- gingival crevicular fluid (GCF) was prepared by inserting filter paper or the like into the gingival sulcus, collecting the exudate, and immersing and eluting in a solvent such as PBS. Good to use.
- samples such as saliva and serum it is better to use those prepared by centrifugation to remove insoluble precipitates.
- the biological sample prepared in this manner is analyzed for its gingipain activity by an enzyme activity measurement method such as an EIA method, an enzymatic measurement method, or a Western plot method. Should be measured.
- the measurement methods themselves that can be used in the present invention are all methods commonly used in the technical field to which the present invention belongs.
- the method for measuring gingipain activity by the EIA method includes, for example, measuring the residual activity after removing an antigen-antibody complex obtained by reacting a biological sample with a specific antibody, in a sample of antibody-free kamen.
- the activity obtained by subtracting the activity from the activity is measured as Rgp activity or Kgp activity.
- a method for measuring gingipain activity by an enzymatic assay is, for example, a method in which a biological sample is reacted with a specific synthetic substrate, and the obtained free fluorescent substrate component is measured with a fluorometer to determine the Rgp activity.
- a fluorometer to determine the Rgp activity.
- it consists of measuring Kgp activity.
- any synthetic substrate that can be applied to gingipain activity measurement can be used.
- Examples of specific substrates for Kg p include, for example, Boc-Val-Leu-Lys-MCA, Z-His-Glu_Lys-MCA, N-p-tosyl-Gly-P ro—Lys—p—Nitroanilide (pNA).
- the gingipain activity measuring method by Western blotting can be performed, for example, by measuring a biological sample by SDS-PAGE.
- the primary antibody that can be used for example, an anti-Rgp-Kgp antibody can be used
- the secondary antibody for example, an HRP-labeled anti-Egret antibody can be used.
- an antibody that reacts with Kgp alone, an antibody that reacts with Rgp alone, and the like can also be used.
- Examples of the antibody that reacts with Kgp alone that can be used as the primary antibody in the present invention include, for example, a synthetic peptide corresponding to 16 amino acids from the N-terminus of the Kgp enzyme active molecule as an antigen, and immune to egrets.
- a polyclonal antibody or the like obtained by the above method can be used.
- an antibody that reacts with Rgp alone for example, a polyclonal antibody obtained by immunizing a heron using antigens obtained by highly expressing and purifying DNA corresponding to the Rgp precursor molecule in Escherichia coli is used. can do.
- Recombinant Rgp used as an antigen is expressed in vector pET so that the Mes (1) to Arg (719) of the translation initiation amino acids are His-tagged at both the N- and C-termini. It is preferable to transform Escherichia coli BL21 with the DNA integrated into 28a and induce its expression with IPTG.
- a polyclonal antibody obtained by mixing Kgp and Rgp purified from the culture supernatant of a gingivalis bacterium and immunizing a heron is used. can do.
- the periodontal disease detection kit according to the present invention is preferably composed of: a sample collection tool; a synthetic toxin-containing reaction solution; and the above-mentioned periodontal disease marker as a positive control.
- the synthetic substrate-containing reaction solution preferably contains, for example, a buffer and a reducing agent in addition to the synthetic substrate.
- Kg p Boc—Val—Leu—Lys—MCA, ZHis—G1 uLys—MCA or N—p—Tosino Gly—Pro—Lys—p—Nitroanilide ( pNA) and the like.
- pNA pNA
- other than Z if it is used for protecting and modifying the terminal of the amino group of the peptide, misalignment can be used.
- Examples of the reducing agent include cysteine, dithiothreitol, and 2-menolecaptoethanol.
- the periodontal disease detection kit according to the present invention can be used, for example, as follows. ⁇ Samples of the subject's saliva and gingival crevicular fluid are collected with a sample collection device such as a lyoper paper, and a predetermined amount of this sample is added to the reaction solution containing the synthetic substrate to react.Then, free AMC is measured with a fluorometer. By measuring, both enzyme activities in the sample can be measured. (Example)
- Gingival sulcus exudate was prepared by inserting Periopaper twice into the gingival sulcus for 30 seconds and collecting it. The paper was eluted by immersing the paper in 200 ⁇ L of PBS and prepared as a sample.
- Saliva or serum was prepared as a sample from which insoluble precipitate was removed by centrifugation at 1500 Orpm for 20 minutes.
- the reaction solution (2 OmM phosphate buffer, ⁇ 7.5, 5 mM cysteine) containing 10-30 ⁇ L of gingival crevicular effusion or saliva prepared in Production Example 1 and a specific synthetic substrate (final concentration ⁇ ⁇ ) is also 40 mL.
- the reaction was stopped by adding 1 mL of 0.1 M acetate buffer (pH 5.0) containing lOmM acetic acid.> Free AMC was measured with a fluorometer (excitation wavelength 38011 m, measurement wavelength 460 nm).
- Example 3 Western blotting (Anti-1 ⁇ ⁇ Kgp antibody was used as the primary antibody) 0.1 mM Leptin and TPCK were added to 10 / z L of the gingival crevicular fluid or saliva prepared in Production Example 1. After mashing (for autolysis), the mixture was treated with a solubilization buffer containing mercaptoethanol at 100 ° C. for 5 minutes, and then SDS-PAGE was performed using a 10% polyacrylamide gel.
- the acrylamide gel after the electrophoresis is overlapped with the nitrocellulose membrane, immersed in a transfer buffer (48 mM Tris, 39 mM glycine, 0.0375% SDS, 20% methanol), and subjected to a 1-hour electric conduction using a semi-dry transfer device ( Then, the protein was transferred to a nitrocellulose membrane.
- a transfer buffer 48 mM Tris, 39 mM glycine, 0.0375% SDS, 20% methanol
- the anti-R gp ⁇ Kg p antibody used as the primary antibody in this example was obtained by immunizing Usagi by mixing Kg p and R g p purified from the culture supernatant of Jinjiharisu bacteria Po It is a clonal antibody.
- Example 4 Western plot method (using an anti-Kgp antibody as the primary antibody)
- the gingival crevicular fluid or saliva prepared in Production Example 1 was used as a primary antibody as an anti-R g P
- the treatment was performed in the same manner as in Example 3 except that 0.69 mg / mL of an antibody that reacts with Kgp alone (anti-Kgp antibody) was used instead of the Kgp antibody, and the enzyme activity was measured.
- the anti-Kgp antibody used in this example is 1 ng from the N-terminus of the Kgp enzyme active molecule.
- Example 5 Western plot method (using an anti-Rgp antibody as the primary antibody)
- Example 3 Except that the gingival crevicular fluid or saliva prepared in Production Example 1 was used as the primary antibody instead of an anti-RgP ⁇ Kgp antibody, an antibody that reacts with Rgp alone (anti-Rgp antibody) was used. And the enzyme activity was measured.
- the anti-Rgp antibody used in the present example was a polyclonal antibody (DNA) obtained by immunizing a egret with antigens obtained by highly expressing and purifying DNA corresponding to the Rgp precursor molecule in Escherichia coli. Antiserum).
- Recombinant Rgp as an antigen was prepared using vector p so that the amino acid translation of the amino acid from Met (1) to Arg (719) at the start of translation would be added to both the N-terminus and the C-terminus.
- Escherichia coli BL21 was transformed with the one integrated into ET 28a, and expression was induced with IPTG.
- the expressed Rgp was recovered in the inclusion body fraction of E. coli, solubilized with 6M guanidine hydrochloride, bound to a nickel column, and refolded by gradually removing the denaturant on the column. After that, purification was performed by elution with imidazole.
- Figure 1 shows the results of the stamp mouth method.
- P g gingivalis cell extract
- E c E. coli cell extract
- P g WT gingivalis wild strain
- P g R gp (-) gingivalis R gp-deficient strain
- P g K gp (-) K. Gingivalis K gp-deficient strain, respectively.
- Kgp and Rgp in saliva collected from type I diabetic patients (D) with no evidence of periodontal disease were measured by the ⁇ ⁇ stamp lot method using anti-Rgp and Kgp antibodies .
- the results are shown in FIGS. 3 and 4.
- P indicates a patient with periodontal disease and C indicates a healthy person.
- Example 6 Kit for detecting periodontal disease
- a periodontal disease detection kit having the following configuration was prepared.
- Periodontal disease markers (Rg p / Kg p) as positive controls
- Periopaper was inserted into the gingival sulcus twice for 30 seconds, and the gingival sulcus was collected and immersed in PBS as a buffer to elute the sample.
- the sample eluted in this manner was added to 1 mL of a reaction solution (20 mM phosphate buffer, pH 7.5, 5 mM cysteine) containing the specific synthetic substrate (final concentration 10 M), and the same procedure as in Example 2 was performed.
- the free AMC was measured by a fluorometer using an enzymatic assay (excitation wavelength 380 nm, measurement wavelength 460 nm). As a result, the same measurement values as obtained in Example 2 were obtained.
- the present invention relates to a cystine protease (gingipain) produced by gingivalis There is a great advantage in that periodontal disease can be reliably and easily detected by using as a marker for detecting periodontal disease.
- the present invention makes it possible to detect periodontal disease reliably and easily by using gingipain as a marker for detecting periodontal disease, and at the same time, to diagnose systemic diseases such as angina pectoris and diabetes. There is also an advantage that can be.
- the method for detecting and diagnosing periodontal disease according to the present invention can provide an extremely useful means that it is possible to diagnose the degree of periodontitis by relative comparison of the amounts of both enzymes.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005506589A JPWO2004106541A1 (ja) | 2003-05-30 | 2004-05-31 | 歯周病マーカー |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003154070 | 2003-05-30 | ||
JP2003-154070 | 2003-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004106541A1 true WO2004106541A1 (ja) | 2004-12-09 |
Family
ID=33487310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/007867 WO2004106541A1 (ja) | 2003-05-30 | 2004-05-31 | 歯周病マーカー |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2004106541A1 (ja) |
WO (1) | WO2004106541A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007016002A (ja) * | 2005-07-11 | 2007-01-25 | Niigata Univ | 歯周病菌プロテアーゼ阻害剤、並びにこれを用いた口腔組成物及び食料品 |
JP2014222241A (ja) * | 2014-07-10 | 2014-11-27 | コルゲート・パーモリブ・カンパニーColgate−Palmolive Company | 口の健康のための代謝産物およびその使用 |
JP2018538534A (ja) * | 2015-12-09 | 2018-12-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多量体抗原に結合するヒトIgG1を直接的に親和性測定する方法 |
JP2019149971A (ja) * | 2018-03-02 | 2019-09-12 | キッコーマン株式会社 | ジンジパインを産生する微生物又はジンジバリス菌を検出する方法及びキット |
WO2020218052A1 (ja) | 2019-04-25 | 2020-10-29 | アドテック株式会社 | 歯周病原因菌の検出方法 |
WO2023276785A1 (ja) | 2021-06-29 | 2023-01-05 | 国立研究開発法人物質・材料研究機構 | 歯周病の体外診断方法、及び、Pg菌検出方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982000641A1 (en) * | 1980-08-25 | 1982-03-04 | Ab Kabivitrum | Peptide substrates for determination of protease activity |
JPH07135973A (ja) * | 1993-11-15 | 1995-05-30 | Suntory Ltd | 歯周病原性菌由来酵素およびその測定方法並びに当該酵素に対する抗体 |
-
2004
- 2004-05-31 JP JP2005506589A patent/JPWO2004106541A1/ja active Pending
- 2004-05-31 WO PCT/JP2004/007867 patent/WO2004106541A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1982000641A1 (en) * | 1980-08-25 | 1982-03-04 | Ab Kabivitrum | Peptide substrates for determination of protease activity |
JPH07135973A (ja) * | 1993-11-15 | 1995-05-30 | Suntory Ltd | 歯周病原性菌由来酵素およびその測定方法並びに当該酵素に対する抗体 |
Non-Patent Citations (3)
Title |
---|
KENJI YAMAMOTO ET AL.: "Shishubyogensei saikin no tanpakushitsu bunkai koso o kaisuru seizon senryaku", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 46, no. 11, 2001, pages 1781 - 1788, XP002983067 * |
KENJI YAMAMOTO ET AL.: "Shishubyogensei saikin protease no kozo to kino no kaiseki", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 42, no. 14, 1997, pages 2425 - 2432, XP002983069 * |
KENJI YAMAMOTO: "Shishubyo no bunshi kiko byogensei protease no kino wa dokomade akirakani saretaka", CELL TECHNOLOGY, vol. 19, no. 2, 2001, pages 295 - 301, XP002983068 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007016002A (ja) * | 2005-07-11 | 2007-01-25 | Niigata Univ | 歯周病菌プロテアーゼ阻害剤、並びにこれを用いた口腔組成物及び食料品 |
JP2014222241A (ja) * | 2014-07-10 | 2014-11-27 | コルゲート・パーモリブ・カンパニーColgate−Palmolive Company | 口の健康のための代謝産物およびその使用 |
JP2018538534A (ja) * | 2015-12-09 | 2018-12-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多量体抗原に結合するヒトIgG1を直接的に親和性測定する方法 |
JP2019149971A (ja) * | 2018-03-02 | 2019-09-12 | キッコーマン株式会社 | ジンジパインを産生する微生物又はジンジバリス菌を検出する方法及びキット |
JP7083663B2 (ja) | 2018-03-02 | 2022-06-13 | キッコーマン株式会社 | ジンジパインを産生する微生物又はジンジバリス菌を検出する方法及びキット |
WO2020218052A1 (ja) | 2019-04-25 | 2020-10-29 | アドテック株式会社 | 歯周病原因菌の検出方法 |
KR20210139351A (ko) | 2019-04-25 | 2021-11-22 | 아도테크 가부시키가이샤 | 치주병 원인균의 검출 방법 |
WO2023276785A1 (ja) | 2021-06-29 | 2023-01-05 | 国立研究開発法人物質・材料研究機構 | 歯周病の体外診断方法、及び、Pg菌検出方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004106541A1 (ja) | 2006-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Veith et al. | Major outer membrane proteins and proteolytic processing of RgpA and Kgp of Porphyromonas gingivalis W50 | |
O'Brien-Simpson et al. | Role of RgpA, RgpB, and Kgp proteinases in virulence of Porphyromonas gingivalis W50 in a murine lesion model | |
Olczak et al. | Iron and heme utilization in Porphyromonas gingivalis | |
Nilsson et al. | Immunoblot assay for serodiagnosis of Helicobacter pylori infections | |
CA2549594A1 (fr) | Nouvelle souche de coronavirus associe au sras et ses applications | |
JPH0235096A (ja) | 抗原組成物およびそれらの製法および用途 | |
JPH08505045A (ja) | tagA遺伝子および消化性潰瘍形成素因の検出方法 | |
CZ96697A3 (en) | Isolated nucleic acid encoding heliobacter pylori antigen, vector in which it is comprised, purified antigenic preparation being encoded thereby, detection method of the heliobacter pylori strain presence, method of determining pre-diathesis for peptic ulcer, method of determining pre-diathesis for stomach carcinoma, heliobacter pylori mutant and heliobacter pylori strain | |
Jones et al. | Cloning and characterization of an α-enolase of the oral pathogen Streptococcus mutans that binds human plasminogen | |
Shen et al. | cDNA cloning and immunologic characterization of Pen o 18, the vacuolar serine protease major allergen of Penicillium oxalicum | |
Mantle et al. | Characterization of aminopeptidases in human kidney soluble fraction | |
Park et al. | Washing-and separation-free electrochemical detection of porphyromonas gingivalis in saliva for initial diagnosis of periodontitis | |
KR20160043984A (ko) | 에이치. 필로리 감염의 검출 방법 | |
KR101650083B1 (ko) | 폐렴연쇄상구균 유래 막소포체 및 이를 이용한 폐렴연쇄상구균 매개 질환 진단 방법 | |
WO2004106541A1 (ja) | 歯周病マーカー | |
Rodrigue et al. | Requirement for nickel of the transmembrane translocation of NiFe‐hydrogenase 2 in Escherichia coli | |
Vogel et al. | Pyruvate Dehyrogenase Component Subunit Structure of the Escherichia coli K 12 Pyruvate Dehydrogenase Complex | |
Jensen et al. | Autoantibodies to pancreatic hsp60 precede the development of glucose intolerance in patients with cystic fibrosis | |
Sztukowska et al. | Disruption of gingipain oligomerization into non-covalent cell-surface attached complexes | |
Taniguchi et al. | Measurement of human serum immunoreactive γ-glutamyl transpeptidase in patients with malignant tumors using enzyme-linked immunosorbent assay | |
Argilés et al. | Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits | |
US8258127B2 (en) | Methods for treating latent tuberculosis | |
Nguyen et al. | Humoral responses to Porphyromonas gingivalis gingipain adhesin domains in subjects with chronic periodontitis | |
US6190667B1 (en) | Methods of inhibiting Helicobacter pylori | |
Krueger et al. | Assignment of functional domains involved in ADP-ribosylation and B-oligomer binding within the carboxyl terminus of the S1 subunit of pertussis toxin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005506589 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |